首页 | 本学科首页   官方微博 | 高级检索  
     

耐药晚期乳腺癌临床研究进展
引用本文:乔华,任建强. 耐药晚期乳腺癌临床研究进展[J]. 国际肿瘤学杂志, 2009, 36(2). DOI: 10.3760/cma.j.issn.1673-422X.2009.02.018
作者姓名:乔华  任建强
作者单位:上海交通大学附属上海市第一人民医院宝山分院肿瘤科,200940;上海交通大学附属上海市第一人民医院宝山分院肿瘤科,200940
摘    要:在临床研究中观察了伊沙匹隆、Larotaxel及新的联合化疗方案治疗耐蒽环和耐紫杉醇类药物的复发转移乳腺癌;类固醇硫酸酯酶抑制物三环氨基硫酸酯及依西美坦联合塞来昔布治疗绝经后耐三苯氧胺的晚期乳腺癌;拉帕替尼、培美曲塞及其联合方案靶向治疗耐曲妥珠HER-2阳性转移乳腺癌.结果显示了良好的疗效及安全性.部分研究结果值得进一步观察.

关 键 词:乳腺肿瘤  药物疗法

Advances of clinical treatment of drug-resistant advanced breast cancer
Abstract:In the current clinical trials,observed treatment on recrudescent and metastatic breast cancer which can be anthracycline-resistant and taxane-resistant with Ixabepilone、Larotaxel and their combination;and treating climacteric-positive and tamoxifen-resistant advanced breast cancer with steroid sulfatase inhibitor STX64 or combination of exemestane and celecoxib;Treating chemotherapy-refractory HER2-positive metastatic breast cancer with lapatinib and pemetrexed as well as their combination.Results have demonstrated superior efficacy and safety,and some of which are worthy of further observation.
Keywords:Breast neoplasms  Drug therapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号